Listing timing unconfirmed
Last verified 9 Oct 2026The previously expected date of 9 Oct 2026 has passed. Trading has not been confirmed.
- IPO valuation
- $384.2MBasic equity value after the offering
- IPO price
- $14.00Per share · USD
- Offering size
- $116.7MBase offering, before overallotment
- Previously expected
- 9 Oct 2026Listing timing unconfirmed
Company overview
TRex Bio websiteThe company focuses on tissue Treg biology to discover and develop medicines designed to restore immune balance and promote tissue repair. Its work addresses unmet needs among patients with autoimmune and inflammatory diseases.
- Company country
- United States
Offering details
USD · Base offering, before overallotment
- Exchange
- Nasdaq Global Select Market
- Ticker
- TRXB
- Shares offered
- 8,333,334
- Shares after offering
- 27,445,682
- New shares
- 8,333,334
- Existing shares sold
- 0
- Gross proceeds to company
- $116.7M
- Gross proceeds to shareholders
- $0
Valuation and offering basis
Basic equity valuation is the price per share multiplied by all shares outstanding immediately after the offering. It is different from enterprise value or fully diluted valuation. Offering size and gross proceeds exclude optional additional shares, fees and expenses. Ranges use the proposed price range; figures are rounded.
IPO timeline
- Registration filedTRex Bio files for an IPO
- Proposed terms publishedTRex Bio sets an IPO price range
- Proposed terms publishedTRex Bio sets an IPO price range
- Proposed terms published
- Final offer price announcedTRex Bio prices its IPO
- Proposed terms published
- Final offer price announcedTRex Bio prices its IPO
- Final offer price announcedTRex Bio prices its IPO
- Final offer price announcedTRex Bio prices its IPO
- Proposed terms published
- Previously expected first trading day · Announced date
Filings and documents
- Pricing announcementChecked 9 Oct 2026 (undated source)View document
- Pricing announcementChecked 9 Oct 2026 (undated source)View document
- Pricing announcementChecked 9 Oct 2026 (undated source)View document
- View document
- View document
- Updated offering termsChecked 6 Oct 2026 (undated source)View document
- View document
- Updated offering termsChecked 5 Oct 2026 (undated source)View document
- View document
- View document
Advisers
- Lead underwriter
- J.P. Morgan Securities LLC
- Lead underwriter
- Evercore Group L.L.C.
- Underwriter
- Cantor Fitzgerald & Co.
- Underwriter
- Stifel, Nicolaus & Company, Inc.
- Underwriter
- Wedbush Securities Inc.